SCHEMBL1346381

SCHEMBL1346381

O=C1NCCC1NCc1ccc(OCc2ccc(F)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
APOL1 O14791 1/20 0.45
PTPN1 P18031 1/20 0.44
S1PR5 Q9H228 1/20 0.44
MAOB P27338 6/20 0.43
APP P05067 1/20 0.43
HTR1A P08908 2/20 0.43
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
KCNH2 Q12809 1/20 0.43
KDM1A O60341 1/20 0.43
NR4A2 P43354 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
PARP10 Q53GL7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7378463 1.00 ALDH1A1 (0.46) ALDH1A1APOL1PTPN1S1PR5MAOB
SCHEMBL1346835 0.93 ALDH1A1 (0.44) ALDH1A1PTPN1S1PR5MAOBAPP
SCHEMBL1344438 0.92 PSEN1 (0.46) ALDH1A1PTPN1S1PR5APPKCNH2
SCHEMBL1347012 0.89 KDM1A (0.52) APOL1KDM1A
SCHEMBL1346696 0.88 FOXM1 (0.46) MAOBAPPNR4A2
SCHEMBL1346938 0.88 MEN1 (0.48) ALDH1A1MAOBAPP
SCHEMBL7370997 0.88 FOXM1 (0.46) MAOBAPPNR4A2
SCHEMBL1346598 0.88 MAOB (0.50) MAOBKCNH2NR4A2
SCHEMBL1345209 0.88 MAOB (0.50) MAOBKCNH2NR4A2
SCHEMBL1346576 0.87 SCN9A (0.49) PTPN1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063039-B2 3-aminopyrrolidone derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2011-11-22 US claimed
US-20100048665-A1 3-AMINOPYRROLIDONE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A., (IT) 2010-02-25 US claimed
EP-1685103-B1 3-AMINOPYRROLIDONE DERIVATIVES NEWRON PHARM SPA (IT) 2008-07-30 EP claimed
US-20070135410-A1 3-Aminopyrrolidone derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-06-14 US claimed
JP-2007511564-A 2007-05-10 JP claimed
EP-1685103-A1 3-AMINOPYRROLIDONE DERIVATIVES Newron Pharmaceuticals S.p.A. (IT) 2006-08-02 EP claimed
WO-2005054190-A1 3-AMINOPYRROLIDONE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A. (IT) 2005-06-16 WO claimed
EP-1533298-A1 3-aminopyrrolidone derivatives Newron Pharmaceuticals S.p.A. (IT) 2005-05-25 EP claimed
EP-0842152-B1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES NEWRON PHARM SPA (IT) 2001-01-31 EP claimed
EP-0842152-A1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES PHARMACIA & UPJOHN S.p.A. (IT) 1998-05-20 EP claimed
WO-1997005111-A1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES PHARMACIA & UPJOHN S.P.A. (IT) 1997-02-13 WO claimed
US-8063039-B2 3-aminopyrrolidone derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2011-11-22 US disclosed
US-7968592-B2 3-aminopyrrolidone derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2011-06-28 US disclosed
US-20100048665-A1 3-AMINOPYRROLIDONE DERIVATIVES NEWRON PHARMACEUTICALS S.P.A., (IT) 2010-02-25 US disclosed
EP-1685103-B1 3-AMINOPYRROLIDONE DERIVATIVES NEWRON PHARM SPA (IT) 2008-07-30 EP disclosed
US-20070135410-A1 3-Aminopyrrolidone derivatives NEWRON PHARMACEUTICALS S.P.A. (IT) 2007-06-14 US disclosed
EP-1533298-A1 3-aminopyrrolidone derivatives Newron Pharmaceuticals S.p.A. (IT) 2005-05-25 EP disclosed
EP-0842152-B1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES NEWRON PHARM SPA (IT) 2001-01-31 EP disclosed
EP-0842152-A1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES PHARMACIA & UPJOHN S.p.A. (IT) 1998-05-20 EP disclosed
WO-1997005111-A1 N-(4-SUBSTITUTED-BENZYL)-2-AMINOLACTAM DERIVATIVES PHARMACIA & UPJOHN S.P.A. (IT) 1997-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135410-A1 3-Aminopyrrolidone derivatives TRPC3, TRPV3, CACNA1D ALDH1A1 773/4885APOL1 2669/4885PTPN1 2475/4885
US-20100048665-A1 3-AMINOPYRROLIDONE DERIVATIVES TRPC3, TRPV3, CACNA1D ALDH1A1 773/4885APOL1 2669/4885PTPN1 2475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.